Interim fluorine-18 fluorodeoxyglucose positron emission tomography forearly metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma

Research output: Contribution to journalArticle


Fluorine-18 fluorodeoxyglucose positron emission tomography is increasingly used by many centers for staging and response assessment of metastatic transitional cell carcinoma. We prospectively evaluated 31 patients undergoing metabolic restaging after only 2 cycles of first-line chemotherapy (PET2). Early metabolic response was associated with patient outcome. The aim was to provide a proof of principle for a risk-adapted approach based on PET2 that may guide new trial design for early-recognized unresponsive patients.

Original languageEnglish
Pages (from-to)433-439
Number of pages7
JournalClinical Genitourinary Cancer
Issue number6
Publication statusPublished - 2014



  • Imaging biomarkers
  • Metabolic response
  • Positron emission tomography
  • Transitional cell carcinoma
  • Urothelial cancer

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Medicine(all)

Cite this